Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide.
Naoe T, Saito A, Hosono N, Kasahara S, Muto H, Hatano K, Ogura M, Masunari T, Tanaka M, Usuki K, Ishikawa Y, Ando K, Kondo Y, Takagi Y, Takada S, Ishikawa M, Choi I, Sano A, Nagai H. Naoe T, et al. Among authors: usuki k. Cancer Immunol Immunother. 2023 Aug;72(8):2865-2871. doi: 10.1007/s00262-023-03432-4. Epub 2023 Apr 24. Cancer Immunol Immunother. 2023. PMID: 37093243 Free PMC article. Clinical Trial.
Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.
Asada N, Ando J, Takada S, Yoshida C, Usuki K, Shinagawa A, Ishizawa K, Miyamoto T, Iida H, Dobashi N, Okubo S, Honda H, Soshin T, Nishimura Y, Tsutsui A, Mukai H, Yamamoto K. Asada N, et al. Among authors: usuki k. Jpn J Clin Oncol. 2023 Jun 29;53(7):595-603. doi: 10.1093/jjco/hyad027. Jpn J Clin Oncol. 2023. PMID: 37017320 Free PMC article. Clinical Trial.
Clinical significance of late CMV disease in adult patients who underwent allogeneic stem cell transplant.
Shimizu H, Najima Y, Kako S, Tanaka M, Fujiwara SI, Mori T, Usuki K, Gotoh M, Hagihara M, Tsukada N, Oniduka M, Takada S, Sakaida E, Fujisawa S, Onoda M, Aotsuka N, Yano S, Ohashi K, Takahashi S, Okamoto S, Kanda Y; Kanto Study Group for Cell Therapy (KSGCT). Shimizu H, et al. Among authors: usuki k. J Infect Chemother. 2023 Dec;29(12):1103-1108. doi: 10.1016/j.jiac.2023.07.015. Epub 2023 Aug 1. J Infect Chemother. 2023. PMID: 37532223
Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocols.
Shimizu H, Kato J, Tanoue S, Kimura SI, Tachibana T, Hatano K, Usuki K, Taguchi J, Hagihara M, Tsukada N, Harada K, Takahashi S, Takada S, Sakaida E, Fujisawa S, Onoda M, Aotsuka N, Handa H, Hatta Y, Nakaseko R, Yano S, Ohashi K, Kanda Y; Kanto Study Group for Cell Therapy (KSGCT). Shimizu H, et al. Among authors: usuki k. Leuk Res. 2024 Sep;144:107562. doi: 10.1016/j.leukres.2024.107562. Epub 2024 Aug 20. Leuk Res. 2024. PMID: 39178610
Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT.
Nakagawa N, Ishiyama K, Usuki K, Takada S, Tomikawa T, Handa H, Katsuoka Y, Hirano D, Sezaki N, Sumi M, Fujisawa S, Taniguchi Y, Mugitani A, Yoshimura T, Ohtsuka E, Takase K, Suehiro Y, Ota S, Kajiguchi T, Maeda T, Yamamoto M, Ohtake S, Katsumi A, Kiyoi H, Matsumura I, Miyazaki Y. Nakagawa N, et al. Among authors: usuki k. Ann Hematol. 2024 Jan;103(1):307-320. doi: 10.1007/s00277-023-05527-5. Epub 2023 Nov 8. Ann Hematol. 2024. PMID: 37940714
Phase II study in children and adults under 40 years with newly diagnosed Langerhans cell histiocytosis: protocol for an LCH-19-MSMFB clinical trial in Japan.
Ono R, Sakamoto K, Kudo K, Sato A, Kudo K, Fujino H, Kawahara Y, Hashimoto H, Doi T, Yanagisawa R, Kawamata T, Miyazaki O, Nakazawa A, Ota Y, Kanegane H, Nakazawa Y, Horibe K, Saito AM, Manabe A, Usuki K, Kiyoi H, Morimoto A, Tojo A, Shioda Y. Ono R, et al. Among authors: usuki k. BMJ Open. 2024 Jun 23;14(6):e084159. doi: 10.1136/bmjopen-2024-084159. BMJ Open. 2024. PMID: 38910000 Free PMC article.
Survival impact of response within the first year in a multicenter prospective observational study of chronic GVHD in a Japanese cohort.
Ohwada C, Sakaida E, Takeda Y, Doki N, Igarashi A, Onizuka M, Toyosaki M, Tanaka M, Tachibana T, Kataoka K, Kato J, Fujisawa S, Kato S, Nakasone H, Naganuma K, Saitoh T, Shono K, Hagihara M, Saito T, Usuki K, Mori T, Nakaseko C, Okamoto S, Kanda Y. Ohwada C, et al. Among authors: usuki k. Int J Hematol. 2024 Sep;120(3):347-355. doi: 10.1007/s12185-024-03813-0. Epub 2024 Jul 17. Int J Hematol. 2024. PMID: 39017858
Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis.
Nagaharu K, Ohya E, Edahiro Y, Hashimoto Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, Kirito K, Wada H, Usuki K, Tanaka T, Mori T, Wakita S, Saito TI, Saito AM, Shimoda K, Kurokawa T, Tomita A, Kiyoi H, Akashi K, Matsumura I, Takenaka K, Komatsu N, Ohishi K, Tawara I, Sugimoto Y. Nagaharu K, et al. Among authors: usuki k. Ann Hematol. 2024 Sep;103(9):3535-3541. doi: 10.1007/s00277-024-05898-3. Epub 2024 Jul 22. Ann Hematol. 2024. PMID: 39037588
Correction to: Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis.
Nagaharu K, Ohya E, Edahiro Y, Hashimoto Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, Kirito K, Wada H, Usuki K, Tanaka T, Mori T, Wakita S, Saito TI, Saito AM, Shimoda K, Kurokawa T, Tomita A, Kiyoi H, Akashi K, Matsumura I, Takenaka K, Komatsu N, Ohishi K, Tawara I, Sugimoto Y. Nagaharu K, et al. Among authors: usuki k. Ann Hematol. 2024 Oct;103(10):4349-4350. doi: 10.1007/s00277-024-05940-4. Ann Hematol. 2024. PMID: 39167184 No abstract available.
325 results